Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of fasudil with MAP chemotherapy in high grade osteosarcoma
jRCTs041220024Phase 1Not yet recruiting
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fasudil in osteosarcoma (OS). Primary endpoints: Dose limiting toxicity and Maximum tolerated dose. Planned start May 2022; status: not yet recruiting.
02
Drugs
fasudil
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on jRCTs041220024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041220024.